ALKERMES INC (ALKS) [Rocket]

Date Filed	Type	Description
07/11/2011	BW	Alkermes to Webcast Analyst and Investor Day
06/27/2011	BW	Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL®, Published in Leading Healthcare Policy Journal
05/31/2011	BW	Alkermes' Corporate Presentation to Be Webcast at Two Upcoming Conferences
05/18/2011	BW	Alkermes Reports Financial Results for Fiscal 2011 and Provides Financial Expectations for Fiscal 2012
05/11/2011	BW	Alkermes to Host Conference Call to Discuss Fiscal Year 2011 Financial Results
05/09/2011	BW	Alkermes Presents Phase 2 Data of ALKS 37 in Late-Breaking Oral Session at Digestive Disease Week Meeting
05/03/2011	BW	Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference
04/27/2011	BW	Data on VIVITROL®, the New FDA-Approved Medication for Prevention of Relapse to Opioid Dependence, Published in The Lancet
04/11/2011	BW	VIVITROL® to be Featured in Data Presentations at American Society of Addiction Medicine Conference
02/28/2011	BW	Alkermes??? Corporate Presentation to Be Webcast at the Cowen Health Care Conference
12/08/2010	BW	Alkermes Announces Results from Phase 2 Study of ALKS 33 in Alcohol Dependence
11/16/2010	BW	Alkermes Presents Promising Preclinical Data on ALKS 33 for Multiple Disease Indications at Annual Meeting of the Society for Neuroscience
11/10/2010	BW	Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference
11/05/2010	BW	Alkermes' Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference
11/04/2010	BW	Alkermes Reports Second Quarter Fiscal 2011 Financial Results
10/28/2010	BW	Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2011
10/25/2010	BW	Alkermes Announces Positive Results from Phase 1 Study of ALKS 33 in Combination with Buprenorphine for Treatment of Cocaine Addiction
10/12/2010	BW	Alkermes Announces FDA Approval of VIVITROL® for Prevention of Relapse to Opioid Dependence
09/20/2010	BW	Alkermes' Corporate Presentation to be Webcast at the UBS Global Life Sciences Conference
09/16/2010	BW	Alkermes Announces FDA Advisory Committee Recommends Approval of VIVITROL® for Opioid Dependence
09/16/2010	BW	Alkermes Stock Trading Halted Today
07/29/2010	BW	Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2011
06/17/2010	BW	Alkermes Announces Notification of Tentative FDA Advisory Committee Meeting to Review VIVITROL® for Opioid Dependence
05/13/2010	BW	Alkermes Reports Financial Results for Fiscal 2010 and Provides Financial Expectations for Fiscal 2011
05/05/2010	BW	Alkermes to Host Conference Call to Discuss Fiscal Year 2010 Financial Results
03/17/2010	BW	Alkermes Announces Initiation of Multidose Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
02/16/2010	BW	Alkermes Announces Positive Results for Phase 1 Study of New Drug Candidate for Treatment of Opioid-Induced Constipation